Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis in Mice via a Toll-Like Receptor 4/p21-Activated Kinase 1 Cascade

Digestive Diseases and Sciences

Volumn 63, Issue 5, 2018, Pages 1210-1218

  Wu, Yaxin ^a   Wu, Jiao ^a   Chen, Ting ^a   Li, Qing ^a   Peng, Wei ^a   Li, Huan ^a   Tang, Xiaowei ^a   Fu, Xiangsheng ^a  

^a THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Fusobacterium nucleatum; p21 activated kinase 1; Toll like receptor 4; Catenin signaling

Indexed keywords

BACTERIAL RNA; BETA CATENIN; CYCLIN D1; P21 ACTIVATED KINASE 1; RESATORVID; RNA 16S; TOLL LIKE RECEPTOR 4; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; P21 ACTIVATED KINASE; PAK1 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FUSOBACTERIUM NUCLEATUM; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA SEQUENCE; TLR SIGNALING; TUMOR NUMBER; ANIMAL; C57BL MOUSE; COLORECTAL TUMOR; DRUG EFFECT; FECES; FLUORESCENCE IN SITU HYBRIDIZATION; INTESTINE FLORA; METABOLISM; MICROBIOLOGY; PATHOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA CATENIN; BIOMARKERS; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; FECES; FUSOBACTERIUM NUCLEATUM; GASTROINTESTINAL MICROBIOME; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; P21-ACTIVATED KINASES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 85045046567     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-018-4999-2     Document Type: Article

References (38)

1. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124:837–848.
2. Tannock GW. The search for disease-associated compositional shifts in bowel bacterial communities of humans. Trends Microbiol. 2008;16:488–495.
3. Jobin C. Colorectal cancer: looking for answers in the microbiota. Cancer Discov. 2013;3:384–387.
4. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014;15:317–328.
5. Viennois E, Merlin D, Gewirtz AT, Chassaing B. Dietary emulsifier-induced low-grade inflammation promotes colon carcinogenesis. Cancer Res. 2016;77:27–40.
6. Wang X, Yang Y, Huycke MM. Microbiome-driven carcinogenesis in colorectal cancer: models and mechanisms. Free Radic Biol Med. 2016;105:3–15.
7. Tozun N, Vardareli E. Gut microbiome and gastrointestinal cancer: les liaisons dangereuses. J Clin Gastroenterol. 2016;50:S191–S196.
8. Whitmore SE, Lamont RJ. Oral bacteria and cancer. PLoS Pathog. 2014;10:e1003933.
9. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22:292–298.
10. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299–306.
11. Marchesi JR, Dutilh BE, Hall N, et al. Towards the human colorectal cancer microbiome. PLoS ONE. 2011;6:e20447.
12. Yu YN, Yu TC, Zhao HJ, et al. Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment. Oncotarget. 2015;6:32013–32026.
13. Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14:207–215.
14. Yu J, Chen Y, Fu X, et al. Invasive Fusobacterium nucleatum may play a role in the carcinogenesis of proximal colon cancer through the serrated neoplasia pathway. Int J Cancer. 2016;139:1318–1326.
15. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14:195–206.
16. Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappa B, and up-regulating expression of microRNA-21. Gastroenterology. 2017;152(851–66):e24.
17. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta BBA Mol Cell Res. 2003;1653:1–24.
18. Behrens J. The role of the Wnt signalling pathway in colorectal tumorigenesis. Biochem Soc Trans. 2005;33(Pt 4):672–675.
19. Fukata M, Shang L, Santaolalla R, et al. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis. 2011;17:1464–1473.
20. Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R. PAK signaling in oncogenesis. Oncogene. 2009;28:2545–2555.
21. Carter JH, Douglass LE, Deddens JA, et al. Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res. 2004;10:3448–3456.
22. Zhu G, Wang Y, Huang B, et al. A Rac1/PAK1 cascade controls beta-catenin activation in colon cancer cells. Oncogene. 2012;31:1001–1012.
23. Chen Y, Peng Y, Yu J, et al. Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade. Oncotarget. 2017;8:31802–31814.
24. Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res. 1986;46:4109–4115.
25. Matsunaga N, Tsuchimori N, Matsumoto T, Ii M. TAK-242 (resatorvid), a small-molecule inhibitor of toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol. 2011;79:34–41.
26. Farzi A, Halicka J, Mayerhofer R, Frohlich EE, Tatzl E, Holzer P. Toll-like receptor 4 contributes to the inhibitory effect of morphine on colonic motility in vitro and in vivo. Sci Rep. 2015;5:9499.
27. Loy A, Arnold R, Tischler P, Rattei T, Wagner M, Horn M. probeCheck—a central resource for evaluating oligonucleotide probe coverage and specificity. Environ Microbiol. 2008;10:2894–2898.
28. Dammann K, Khare V, Harpain F, et al. PAK1 promotes intestinal tumor initiation. Cancer Prev Res (Phila). 2015;8:1093–1101.
29. Guo J, Fu X, Liao H, et al. Potential use of bacterial community succession for estimating post-mortem interval as revealed by high-throughput sequencing. Sci Rep. 2016;6:24197.
30. Caporaso JG, Lauber CL, Walters WA, et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 2012;6:1621–1624.
31. Irrazabal T, Belcheva A, Girardin SE, Martin A, Philpott DJ. The multifaceted role of the intestinal microbiota in colon cancer. Mol Cell. 2014;54:309–320.
32. Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65:1973–1980.
33. Sena P, Saviano M, Monni S, et al. Subcellular localization of beta-catenin and APC proteins in colorectal preneoplastic and neoplastic lesions. Cancer Lett. 2006;241:203–212.
34. Zhu G, Wang Y, Huang B, et al. A Rac1/PAK1 cascade controls β-catenin activation in colon cancer cells. Oncogene. 2012;31(8):1001–1012.
35. Ding T, Schloss PD. Dynamics and associations of microbial community types across the human body. Nature. 2014;509:357–360.
36. Abed J, Emgard JE, Zamir G, et al. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe. 2016;20:215–225.
37. Lyra A, Forssten S, Rolny P, et al. Comparison of bacterial quantities in left and right colon biopsies and faeces. World J Gastroenterol. 2012;18:4404–4411.
38. Conte MP, Schippa S, Zamboni I, et al. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 2006;55:1760–1767.